Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2973144 | 0.95 | HPGD (0.45) | KMT2AHPGDMEN1MRGPRX4CYP1A2 | |
| SCHEMBL2975969 | 0.90 | GPR132 (0.43) | HPGDMRGPRX4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4065690 | 0.89 | BRD4 (0.39) | KMT2AMEN1MRGPRX4GPR132ABL1 | |
| SCHEMBL2975345 | 0.89 | MAOB (0.49) | KMT2AHPGDMRGPRX4CYP1A2CYP2C9 | |
| SCHEMBL1379654 | 0.88 | KMT2A (0.57) | KMT2AHPGDMEN1NPC1POLB | |
| SCHEMBL2970729 | 0.88 | HPGD (0.47) | KMT2AHPGDMEN1NPC1MRGPRX4 | |
| SCHEMBL2969649 | 0.88 | MRGPRX4 (0.44) | HPGDMRGPRX4GPR132ABL1 | |
| SCHEMBL4066534 | 0.84 | MRGPRX4 (0.40) | HPGDMRGPRX4CYP1A2CYP2C9MAPK1 | |
| SCHEMBL2974343 | 0.84 | LMNA (0.51) | HPGDNPC1POLBCYP1A2CYP2C9 | |
| SCHEMBL1381948 | 0.83 | HPGD (0.60) | KMT2AHPGDMEN1NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767673-B2 | N-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | claimed |
| EP-1658289-B1 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARM INC (US) | 2009-03-18 | — | — | EP | claimed |
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | claimed |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | CASTELHANO ARLINDO L | 2008-09-11 | — | — | US | claimed |
| JP-2007502822-A | — | — | 2007-02-15 | — | — | JP | claimed |
| EP-1658289-A2 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | CASTELHANO ARLINDO L | 2006-02-16 | — | — | US | claimed |
| WO-2005021544-A2 | N3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-7767673-B2 | N-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1658289-B1 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARM INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-7442709-B2 | N3-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | CASTELHANO ARLINDO L | 2008-09-11 | — | — | US | disclosed |
| EP-1658289-A2 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | CASTELHANO ARLINDO L | 2006-02-16 | — | — | US | disclosed |
| WO-2005021544-A2 | N3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | KIT, ABL1, CHUK | KMT2A 386/4885HPGD 666/4885MEN1 934/4885 |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | KIT, ABL1, CHUK | KMT2A 333/4885HPGD 1281/4885MEN1 696/4885 |
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | KIT, ABL1, CHUK | KMT2A 333/4885HPGD 1281/4885MEN1 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.